Business Wire

CA-XPRIZE

8.4.2020 14:02:04 CEST | Business Wire | Press release

Share
XPRIZE Taps Visionary Sci-Fi Writers to Imagine the Future of Telepresence Technologies

XPRIZE , the global leader in incentivized prize competitions, in partnership with ANA , Japan’s 5-star airline, announce Avatars Inc , a unique online anthology that blends original science fiction stories with a writing competition to imagine novel use-cases of telepresence technology in the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005209/en/

The anthology, edited by Ann VanderMeer, includes 24 original pieces by high-profile authors including James SA Corey, Adrian Tchaikovsky, Tade Thompson, Pat Cadigan, JY Yang, Ken Liu, Charles Yu, Paul McAuley, K Chess, Johanna Sinisalo, and Aliette de Bodard.

The premise for the anthology is as follows:

Established in 2038, Avatars Inc is the world’s leading producer of robotic avatar systems that can transport a human’s senses, actions, and presence to a remote location in real time. For the next few decades, they developed hundreds of avatar models and enabled millions of operator-hours. In 2080, a campaign was underway to physically retrieve, preserve and archive the memories from their most valuable units. We have been searching the world, and even deep into the solar system, to acquire the chips that contain avatar memories spanning the 21st century. These are those memories.

The short story contest is open through May 8, 2020 and is open to anyone over the age of 18 who submits an original story between 2,500 – 3,500 words, bringing to life a ‘missing’ avatar memory. Members of XPRIZE’s Science Fiction Advisory Council will vote on the finalist pieces to select the grand prize winner, who will then receive a prize package including a 3.2GHz 8-core Intel Xeon W Processor iMac Pro, a GoPro Hero7 Camera, Sony noise cancelling headphones, a 32GB Kindle Paperwhite, a JoneR Universal Translator, and more.

The fictional Avatars Inc was inspired by the real-life $10 million ANA Avatar XPRIZE , a four-year global competition focused on the development of an avatar system that can transport a human’s senses, actions, and presence to a remote location in real time. The competition was launched in March 2018 at South by Southwest (SXSW) in Austin.

“The world of Avatars Inc was made possible by the incredible partnership between XPRIZE and ANA and is intended to elevate the overall conversation about avatars among the general public, making the topic of avatars accessible, relevant and exciting, while creating demand and interest in the technologies that will result from the ANA Avatar XPRIZE,” said David Locke, Prize Lead of the ANA Avatar XPRIZE.

As of January 2020, a total of 77 teams from 19 countries qualified to compete. In March 2022, up to 20 teams will compete in the finals, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use-case scenarios. The first-place winner will receive $5 million.

To explore the world of Avatars Inc, and to submit your short story, visit http://www.avatars.inc .

About XPRIZE

XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye